Understanding how DNA repair issues affect Ewing sarcoma in children and adolescents
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
This study is looking at how problems with repairing DNA might lead to Ewing sarcoma, a type of cancer that affects kids and teens, to help find better ways to treat and understand the disease.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931447 on NIH RePORTER |
What this research studies
This research investigates the role of DNA damage repair deficiencies in the development of Ewing sarcoma, a serious bone and soft tissue cancer affecting children and adolescents. By analyzing genetic data and tumor samples, the study aims to identify specific genetic variants that may contribute to the disease's progression. The research employs both computational methods and experimental models to better understand how these genetic factors influence treatment outcomes and risk assessment for patients. Ultimately, the goal is to improve risk stratification and treatment strategies for those diagnosed with Ewing sarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents diagnosed with Ewing sarcoma, particularly those with a family history of DNA repair deficiencies.
Not a fit: Patients with Ewing sarcoma who do not have any identifiable genetic predispositions related to DNA damage repair may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans and improved outcomes for patients with Ewing sarcoma.
How similar studies have performed: Previous research has shown promising results in understanding the genetic underpinnings of Ewing sarcoma, indicating that this approach may yield valuable insights.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Gillani, Riaz — Dana-Farber Cancer Inst
- Study coordinator: Gillani, Riaz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.